The Serum Level Of CXCL12, PDGF, CXCL14in Acute Optic Neuritis And Its Assosiation With Prognosis

Objective:To describe clinical characteristic and follow up of acute optic neuritis (AON),analyzing its general immunity index and prognosis. To detect the serum level ofchemokine12(CXCL12), platelet-derived growth factor (PDGF), and chemokine14(CXCL14) in optic neuritis and other demyelination diseases, analyzing thedifferentiation of these factors.Methods:We collected clinical data of AON patients in ophthalmology of general hospital of PLAform Mar1,2012to Feb28,2013for12month follow up. Venous blood of ON andother demyelination diseases were collected and divided into groups. Enzyme-linkedimmunosorbent assay was used in measuring the serum level of CXCL12, PDGF andCXCL14.Results:1. Clinical characteristic and treatment effect: AON is more in young women aged31.60±10.47, male/female ratio1/3.4. Obvious causes appeares in40.3%patients. MRIabnormal signals are detected in30.2%patients. Best corrected visual acuity(BCVA) is0.06±0.10during an attack. BCVA gradually recovered after steroid pulse therapy,1month0.42±0.27,3month0.75±0.34,6month0.83±0.30,12month0.86±0.27.2. Immunity index and prognosis:19.3%patients are positive of serum aquaporin4antibody,17.6%patients are positive of other serum antibodies,4.2%patient arepositive for oligoclonal bands in cerebrospinal fluid.16.0%patients have another attackin following12months, including13.4%recurrence of optic neuritis,0.8%becomingMS and1.7%becoming NMO. However, it has no correlation between immunity indexand prognosis in the following12months.3. Serum level of CXCL12: The serum level of CXCL12in different groups are healthycontrol group(HC)0.207±0.150ng/ml, acute optic neuritis group(AON)0.136±0.076ng/ml, catabatic optic neuritis group(CON)0.431±0.276ng/ml, acuteneuromyelitis optica spectrum diseases group(ANMOSDs)0.281±0.257ng/ml, catabaticneuromyelitis optica spectrum diseases group(CNMOSDs)0.270±0.132ng/ml, neuromyelitis optica group(NMO)0.498±0.221ng/ml, and multiple sclerosis group(MS)0.439±0.174ng/ml.4. Serum level of PDGF: The serum level of PDGF in different groups are HC40.944±14.677pg/ml, AON25.771±5.094pg/ml, CON34.359±4.567pg/ml, ANMOSDs32.589±8.957pg/ml, CNMOSDs38.805±10.449pg/ml, NMO48.982±12.985pg/ml, andMS50.498±6.322pg/ml.5. Serum level of CXCL14: The serum level of CXCL14in different groups are HC2.149±1.783ng/ml, AON1.312±1.127ng/ml, CON4.740±2.281ng/ml, ANMOSDs2.111±1.351ng/ml, CNMOSDs2.127±1.739ng/ml, NMO7.096±5.198ng/ml, and MS2.409±1.009ng/ml.Conclusions:1. AON is more in young women, nearly half of them have obvious causes before theattack. Abnormal signals could detect in MRI.2. Steroid pulse therapy has definite effect, and BCVA have a remarkable recovery infirst trimester.3. Immunity index abnormal could detect in AON, however, no obvious associationfigured out in the following12months.4. The AON serum level of CXCL12, PDGF and CXCL14decrease, and increase evenhigh than HC as symptom get recovered.5. The serum level of CXCL12and CXCL14have no obvious distinction in differentstage of NMOSDs. The serum level of PDGF are low in acute stage and high incatabatic stage, but lower than HC at the time.6. The serum level of CXCL12in non-acute stage of NMO and MS are higher than HC,but no obvious distinction. The serum level of CXCL14in Non-acute stage of NMO arehigher than HC.7. NMOSDs and NMO may have obvious differences in prognosis and mechanism ofnerve regeneration, which lead to the differentiation of serum level of CXCL12, PDGFand CXCL14.